Page 3«..2345..1020..»

UTSA Presidential Lecture featuring Leonard Pinchuk – UTSA Today

UTSA Presidential Lecture featuring Leonard Pinchuk UC Retama Auditorium 2.02.021 UTSA Circle – San Antonio

29.5843443-98.6173559

Date/Time: 09/14/201711:00 am – 12:00 pm

Location:UC Retama Auditorium 2.02.021 UTSA CircleSan Antonio,

United States

Leonard Pinchuk Ph.D., D.Sc., (h.c.), NAE presents

Dr. Leonard Pinchuk, recipient of BioMed SAs 2017 Award for Innovation in Healthcare and Bioscience, is a serial inventor and entrepreneur with over 120 issued U.S. patents and 80 publications, and has co-founded 10 biomedical companies. His major accomplishments include the invention of the worlds first commercially successful and most widely used angioplasty balloon catheters, the helical wire stent, the modular stent-graft, a drug-eluting stent (TAXUS), two biostable implantable biomaterials (polycarbonate urethane and poly(styrene-block-isobutylene-block-styrene)), a novel glaucoma shunt (InnFocus MicroShunt) and the next generation intraocular lens material.He received a B.Sc. in Chemistry from McGill University (1976), a Ph.D. interdisciplinary in Engineering and Chemistry from the University of Miami (1984) and an honorary Doctor of Science degree from McGill University (2005). He was inducted into AIMBE in 2007 and the National Academy of Engineering in 2012 and is the recipient of the 2017 Society for Biomaterials Technology, Innovation and Development Award.Dr. Pinchuk began his career in 1983 at Cordis Corporation and left in 1987 to co-found Corvita Corporation (angioplasty catheters, vascular grafts, stents, stent-grafts) which went public on the NASDAQ in 1994, was acquired by Pfizer, Inc. in 1996, and was then sold to Boston Scientific Corporation in 1998. Dr. Pinchuk founded Innovia LLC in 2002 and continues to serve as President and CEO. Innovia has incubated eight companies working in the fields of intraocular lenses, glaucoma shunts, radiation oncology catheters, urinary catheters, gene therapy and futuristic biomaterials. One of the Innovia spin-offs, InnFocus, Inc., developed a novel medical device to treat glaucoma and was acquired by Santen Pharmaceuticals in August 2016. Dr. Pinchuk will continue to serve as InnFocus CSO for the next three years. Dr. Pinchuk also enjoys an appointment as Research Professor of Biomedical Engineering at the University of Miami (Miami, FL).

Follow this link:
UTSA Presidential Lecture featuring Leonard Pinchuk – UTSA Today

Recommendation and review posted by Bethany Smith

New ‘hit-and-run’ gene editing tool temporarily rewrites genetics to treat cancer and HIV – GeekWire

Nanoparticles (orange) deliver temporary gene therapy to immune cells (blue) to give them disease-fighting tools. (Fred Hutch Illustration / Kimberly Carney)

CAR T immunotherapies are all the rage in the medical community, reprogramming a patients immune system to fight cancer. For some patients, theyve produced near-miraculous recoveries, and they could be a huge breakthrough in cancer treatment.

The business community is taking note as well: Kite Pharma, a biotech company developing these therapies, announced a deal to be acquired for $11.9 billion on Monday, sending stock prices of Seattle immunotherapy developer Juno Therapeuticsskyrocketing.

But there are still giant pitfalls to using the therapies on a large scale because they are incredibly complex and expensive to produce. Researchers from Seattles Fred Hutchinson Cancer Research Center are taking the problem head-on with new hit-and-run gene editing technology.

In a study published Wednesday in the journal Nature Communications, researchers led by Dr.Matthias Stephan reported they have developed a nanoparticle delivery system that can temporarily alter cells so they are able to fight cancer and other diseases.

The best part? The treatment is a powder that just needs to be mixed with water to activate and even better, it could be an essential breakthrough in making cutting-edge medical technology affordable for patients.

Stephan told GeekWire in a previous piece on the technology that his goal is to make immunotherapy so easy to access that it replaces chemotherapy as the front-line treatment for cancer.

What I envision is like the Walgreens flu shot scenario, or you go to your doctor and you get hepatitis B shot, he said at the time. You go there every Friday, and thats it.

We realized in order to outcompete chemotherapy, we have to design something that is at least as affordable and can be manufactured at large scale by one biotech company and shipped out to local infusion centers, Stephan said. At the moment, CAR T cell therapies must be made individually for each patient in specialized labs.

Heres how the new tech works: The nanoparticles designed by Stephan and his team act like shipping containers for bundles of mRNA, the molecules that tell cells how to build disease-fighting proteins. The nanoparticles also have molecules attached to the outside to help them find the right kind of cells, like a shipping label on a package.

When the mRNA is delivered to the cell, it prompts the cell to grow disease-fighting features, like the chimeric antigen receptor in CAR T cells that help them identify and kill cancer.Researchers said the technology could potentially be used to develop treatments for HIV, diabetes and other immune-related diseases.

In the short run, the tech could help researchers discover new treatments and therapies in the lab. It could one day be used in hospitals and clinics around the world, but will first need to undergo extensive clinical trials to ensure the tech is effective and safe to use in humans.

Read more from the original source:
New ‘hit-and-run’ gene editing tool temporarily rewrites genetics to treat cancer and HIV – GeekWire

Recommendation and review posted by sam

Why the federal government urgently needs to fund more cancer research – Los Angeles Times

Two weeks ago I lay in a hospital bed at the University of Pennsylvanias Perelman Center for Advanced Medicine and watched a clear, garlicky-smelling bag of my re-engineered white blood cells drip into my veins.

The bag contained not only my collected T cells but also magic sauce from Novartis, the drug company financing a trial of a gene therapy for my specific mutation of multiple myeloma, a blood cancer.

This living drug, a CAR-T treatment, may revitalize my immune system and erase my myeloma tumors and save my life. It could also kill me.

Last month, the Federal Drug Administration approved the first CAR-T therapy, Kymriah, to treat a leukemia that mainly affects children. My myeloma trial is an outgrowth of that promising effort. Researchers say that just one of my retooled cells can kill 100,000 cancer cells, and theyve infused millions of them.

But no one can guarantee me a happy ending. From my research, I figure I have a 1-in-9 shot at beating my wily myeloma and then for only a year or so.

Still, I consider myself lucky. Fewer than 5% of cancer patients will get into potentially beneficial clinical trials this year, and I am one of them.

Since 2003, under Democratic and Republican administrations, the National Institutes of Health budget has been cut by 15.5%, after inflation. This has left far too little NIH money for basic research and prevention, including for oncology trials. Drug companies now underwrite about 71% of the thousands of cancer trials that are conducted in the U.S. each year.

This sets back basic cancer research in several ways. Because drug companies are investing millions, if not billions, to develop proprietary, patented medicines, they dont share their discoveries as openly as the NIH does. Perhaps worse, they recklessly duplicate trials for certain common cancers, such as melanoma, to the point where around 40% fizzle out for a lack of patients to test.

By contrast, my doctors and I couldnt find a trial slot for my disease, from Seattle to Hackensack, except for the very last opening at Perelman.

Initially I was rated behind another desperately ill person and received a gut-punch email: We can not offer you a spot. In the end, I replaced a sick patient who did not meet the trials strict protocols, even though the patient needed treatment as much, or more, than I did.

Leading medical scientists say it is in our national interest to fund far more research, especially in cutting-edge immunology, which appears close to curing blood cancers. But although there is surely room in President Trumps 2018 federal budget of $4.1 trillion to fund more government cancer trials, he wants to cut the NIH’s budget further, by nearly 20%.

To think we are going to stop funding biomedical studies and lose skilled scientists seems almost crazy, Dr. Stephen Grupp, a leading leukemia researcher at the Childrens Hospital of Philadelphia, told me. This is the time to invest, not back off.

The American Cancer Societys chief medical officer, Dr. Otis Brawley, noted in a telephone interview that the Department of Defense spends about as much money on bands and music as the NIH spends on breast cancer: Where are our national priorities?

If we do not invest in more research, there is a good chance that we could cede our leadership in biomedical innovation to China or other countries. Had I not gotten the last slot at Perelman, my oncologist was suggesting we explore Beijing, where Chinese researchers are reporting incredible myeloma outcomes. All I had to do to get a trial slot, apparently, was hand over $50,000 cash.

Whether the breakthroughs happen in Philadelphia, Seattle or Beijing, cures for diseases like mine are on the horizon. The sum of medical knowledge doubles every 73 days or so. Researchers, including my own doctor at Perelman, foresee a day in the early 2020s when people with blood cancers will be cured by precision medicine immunology as outpatients.

Millions of patients will follow me, and many of them will be cured. But they could be cured in the next two or three years, rather than five to seven, if Trump were aggressively expanding the NIH budget. Starting by, say, buying fewer Army bass drums and more cancer bullets.

Frank Lalli was the founding editor of New West magazine. He is the author of Your Best Health Care Now.

Follow the Opinion section on Twitter @latimesopinion or Facebook

The rest is here:
Why the federal government urgently needs to fund more cancer research – Los Angeles Times

Recommendation and review posted by sam

Kate’s morning sickness probably not dangerous, doctors say – CBS News

Last Updated Sep 5, 2017 2:06 PM EDT

Along with the announcement that Britain’s Prince William and his wife, the Duchess of Cambridge, are expecting their third child, the couple revealed that for the third time as with her previous two pregnancies the former Kate Middleton is suffering from hyperemesis gravidarum, or severe morning sickness.

Hyperemesis gravidarum is estimated to affect about one to three percent of pregnant women and can result in nausea and vomiting so acute that hospitalization is required. It is thought to be caused by pregnancy hormones, but doctors aren’t sure why some women experience worse symptoms than others.

The condition usually begins in the early weeks of pregnancy and in many cases, subsides by about 20 weeks. But for some women, the effects may persist until the baby is born.

The condition can be “absolutely devastating,” said Dr. Roger Gadsby of Warwick University, who has studied the issue for decades. “Your life is on hold while the symptoms are present,” he said, noting that some pregnant women may vomit dozens of times per day and be restricted to bed rest.

Kensington Palace made the pregnancy announcement Monday, saying the duchess was not feeling well enough to attend an official engagement later in the day. Kate is being cared for at her Kensington Palace home in London. Officials did not announce when the baby is due, but the duchess is believed to be less than 12 weeks pregnant.

She and Prince William already have two children: Prince George, 4 and Princess Charlotte, 2.

At a public appearance in Oxford on Tuesday, William said the royal couple is happily anticipating baby No. 3.

“It’s very good news,” he said, adding, “It’s always a bit anxious to start with, but yeah she’s very good.”

In 2012, Kate was hospitalized for several days when she was believed to be suffering from dehydration during her first pregnancy.

“People can get dehydrated very quickly so [a woman] might need to come in after a day or two,” Dr. Jeff Chapa, head of the section of maternal fetal medicine at the Cleveland Clinic, explained to CBS News at the time.

Chapa said virtually all pregnant women experience some degree of morning sickness during the first three months of pregnancy, which is caused by the release of HCG hormone from the placenta. But if a woman can’t keep anything down down and feels particularly weak, those are signs that she may need to get evaluated by a doctor for hyperemesis gravidarum.

There is no evidence that the nausea and vomiting from severe morning sickness will affect the baby’s future health. Women with the condition actually have a slightly lower risk of miscarriage, according to Britain’s Royal College of Obstetricians and Gynaecologists.

In severe cases, however, babies can be born with lower than expected birthweight. Women with the condition are advised to eat small meals often, to avoid any foods or smells that trigger symptoms and to consult their midwife or doctor if their symptoms do not subside.

If treatment requires hospitalization, women are typically given vitamins, steroids and anti-nausea drugs intravenously. Patients are also sometimes treated with shots of heparin, to thin their blood: pregnant women are at increased risk of developing blood clots in their legs, and being dehydrated further elevates the risk.

Gadsby said he would expect doctors to be able to treat the duchess at Kensington Palace and that there shouldn’t be any lasting effects. She would likely have to cut back on her royal schedule, though.

“As long as the mom receives adequate treatment, the mom is usually fine and the baby is fine,” he said.

2017 CBS Interactive Inc. All Rights Reserved. This material may not be published, broadcast, rewritten, or redistributed. The Associated Press contributed to this report.

Continue reading here:
Kate’s morning sickness probably not dangerous, doctors say – CBS News

Recommendation and review posted by sam

Male Hypogonadism Drug Market Analysis, Share and Size, Trends, Industry Growth And Segment Forecasts To 2021 – satPRnews (press release)

Male Hypogonadism DrugMarketreport provides key statistics on the market status of the Male Hypogonadism DrugManufacturers and is a valuable source of guidance and direction for companies and individuals interested in the Male Hypogonadism DrugIndustry. The Male Hypogonadism Drugindustry report firstly announced the Male Hypogonadism DrugMarket fundamentals: definitions, classifications, applications and market overview; product specifications; manufacturing processes; cost structures, raw materials and so on.

Global and Chinese Male Hypogonadism DrugIndustry report 2012-2022 Provides professional and in-depth study on the current state of the global Male Hypogonadism Drugmarket with a focus on the Chinese market.

Get PDF Sample of Male Hypogonadism DrugMarket Report @ https://www.360marketupdates.com/enquiry/request-sample/10817841

Table of Contents:

Chapter 1 Overview of Male Hypogonadism DrugMarket1.1 Brief Overview of Male Hypogonadism DrugIndustry1.2 Development of Male Hypogonadism DrugMarket1.3 Status of Male Hypogonadism DrugMarket

Chapter 2 Manufacturing Technology of Male Hypogonadism DrugIndustry2.1 Development of Male Hypogonadism DrugManufacturing Technology2.2 Analysis of Male Hypogonadism DrugManufacturing Technology2.3 Trends of Male Hypogonadism DrugManufacturing Technology

Chapter 3 Analysis of Global Male Hypogonadism DrugMarket Key Manufacturers3.1.1 Company Profile3.1.2 Product Information3.1.3 2012-2017 Production Information3.1.4 Contact Information

Inquire for further detailed information about Male Hypogonadism DrugMarket Report @ https://www.360marketupdates.com/enquiry/pre-order-enquiry/10817841

Chapter 4 Global and Chinese Male Hypogonadism DrugMarket4.1 2012-2017 Global Capacity, Production and Production Value of Male Hypogonadism DrugMarket4.2 2012-2017 Global Cost and Profit of Male Hypogonadism DrugMarket4.3 Male Hypogonadism DrugMarket Comparison of Global and Chinese Male Hypogonadism DrugIndustry4.4 2012-2017 Global and Chinese Supply and Consumption of Male Hypogonadism DrugMarket4.5 2012-2017 Chinese Import and Export of Male Hypogonadism Drug

Chapter 5 Market Status of Male Hypogonadism DrugIndustry5.1 Male Hypogonadism DrugMarket Competition of Industry by Company5.2 Market Competition of Industry by Country (USA, EU, Japan, Chinese etc.)5.3 Male Hypogonadism DrugMarket Analysis of Consumption by Application/TypeContinue

In the end, Male Hypogonadism DrugMarket report provides the main region, market conditions with the product price, profit, capacity, production, supply, demand and market growth rateand forecast etc. Male Hypogonadism DrugMarket report also Present new project SWOT analysis, investment feasibility analysis, and investment return analysis.

Continue reading here:
Male Hypogonadism Drug Market Analysis, Share and Size, Trends, Industry Growth And Segment Forecasts To 2021 – satPRnews (press release)

Recommendation and review posted by simmons

Asia-Pacific Male Hypogonadism Market by Region, Production, Consumption, Revenue, Market Share and Growth … – satPRnews (press release)

MarketResearchNest.com adds Asia-Pacific Male Hypogonadism Market Report 2017new report to its research database. The report spread across 113 pages with multiple tables and figures in it.

This report studies the Asia-Pacific Male Hypogonadism market status and outlook of global and major regions, from angles of manufacturers, regions, product types and end industries; this report analyzes the top manufacturers in global and major regions, and splits the Asia-Pacific Male Hypogonadism market by product type and applications/end industries.

The global Asia-Pacific Male Hypogonadism market is valued at XX million USD in 2016 and is expected to reach XX million USD by the end of 2022, growing at a CAGR of XX% between 2016 and 2022.

Browse full table of contents and data tables at

https://www.marketresearchnest.com/asia-pacific-male-hypogonadism-market-report-2017.html

Major players in the market are identified through secondary research and their market revenues determined through primary and secondary research. The major players in Asia-Pacific Male Hypogonadism market include

Astrazeneca Plc., Merck & Co. Inc., Laboratories Genevrier, Allergan Plc., Endo International Plc., Ferring, AbbVie Inc., Eli Lilly and Company Ltd., Finox Biotech, Teva Pharmaceutical Industries Ltd., Bayer AG, IBSA Institut Biochimque.

Geographically, this report is segmented into several key Regions, with production, consumption, revenue, market share and growth rate of Asia-Pacific Male Hypogonadism in these regions, from 2012 to 2022 (forecast), covering

China, Japan, South Korea, Taiwan, India, Southeast Asia, Australia.

Asia-Pacific Male Hypogonadism Market (K Units) and Revenue (Million USD) Market Split by Regions

Order a Purchase Report Copy @ https://www.marketresearchnest.com/purchase.php?reportid=256714

On the basis of product, the Asia-Pacific Male Hypogonadism market is primarily split intoTestosterone Replacement Therapy, Gonadotropin-Releasing Hormones Therapy.

Asia-Pacific Male Hypogonadism Market (K Units) and Revenue (Million USD) Market Split by Product Type

On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, consumption (sales), market share and growth rate of Asia-Pacific Male Hypogonadism for each application, including:

Kallmann Syndrome, Klinefelters Syndrome, Pituitary Disorders, Others.

Asia-Pacific Male Hypogonadism Market (K Units) and Revenue (Million USD) Market Split by end users

This research study involved the extensive usage of both primary and secondary data sources. The research process involved the study of various factors affecting the industry, including the government policy, market environment, competitive landscape, historical data, present trends in the market, technological innovation, upcoming technologies and the technical progress in related industry, and market risks, opportunities, market barriers and challenges. The following illustrative figure shows the market research methodology applied in this report.

All possible factors that influence the markets included in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data. The market size for top-level markets and sub-segments is normalized, and the effect of inflation, economic downturns, and regulatory & policy changes or other factors are not accounted for in the market forecast.

Request a sample copy at

https://www.marketresearchnest.com/requestsample.php?reportid=256714

About Us:

MarketResearchNest.com is the most comprehensive collection of market research products and services on the Web. We offer reports from almost all top publishers and update our collection on daily basis to provide you with instant online access to the worlds most complete and recent database of expert insights on global industries, organizations, products, and trends.

Contact Us

Mr. Jeet Jain

Sales Manager

sales@marketresearchnest.com

+1-240-284-8070(U.S)

+44-20-3290-4151(U.K)

Connect with us: Google+ | LinkedIn | Twitter | Facebook

See the article here:
Asia-Pacific Male Hypogonadism Market by Region, Production, Consumption, Revenue, Market Share and Growth … – satPRnews (press release)

Recommendation and review posted by Bethany Smith

Lundin Mining Announces 2017 Mineral Resource and Mineral Reserve Estimates – MarketWatch

TORONTO, ONTARIO, Sep 05, 2017 (Marketwired via COMTEX) — TORONTO, ONTARIO–(Marketwired – Sept. 5, 2017) – Lundin Mining Corporation (LUN)(omx:LUMI)(“Lundin Mining” or the “Company”) today reported its Mineral Resource and Mineral Reserve estimates as at June 30, 2017. On a consolidated and attributable basis, contained metal in the Proven and Probable Mineral Reserve categories totaled 3,232 kt of copper, 3,415 kt of zinc and 130 kt of nickel.

Commenting on the update, Mr. Paul Conibear, President and CEO of Lundin Mining said “We are pleased that our exploration efforts continue to add great value to our assets. Exploration success at Candelaria has resulted in further significant increases in underground Mineral Resources and Mineral Reserves that will allow us to continue to advance mine plan optimization and mine life extension in Chile. Study work and approval of the Zinc Expansion Project at Neves-Corvo and the Eagle East development at Eagle during the last year have contributed to increased Mineral Reserves at both mines. In the light of improved market conditions, we plan to accelerate exploration at all our mine sites in 2018 as well as advance at least two new copper-focused greenfield exploration projects”.

Highlights

Total Candelaria Measured and Indicated MineralResources have increased by approximately 7.5% to 740.9Mt at 0.70%Cu, from 689.0 Mt at 0.64% Cu reported as of June 30, 2016, reflecting thecontinued success of the exploration campaigns.

Total Candelaria Proven and Probable MineralReserves have increased by approximately 3% to 497.5Mt at 0.56% Cu,despite mining depletion. The open pit Proven and Probable MineralReserves, excluding stockpiles, have decreased to 315.9 Mt at 0.53% Cu, from337.6 Mt at 0.54% Cu reported as of June 30, 2016, reflecting 12 months ofdepletion by mining.

Total Candelaria Underground Proven and ProbableMineral Reserves now stand at 89.3 Mt at 0.88% Cu. This is a significantincrease of 38.1 Mt over last year reflecting continued explorationsuccess, particularly in the Candelaria Norte underground mine.

An initial Eagle East Probable Mineral Reservewas reported on April 10, 2017 containing 1.5Mt at 3.7% Ni and 3.0%Cu. The total combined Eagle and Eagle East Proven and Probable MineralReserves now stand at 4.7 Mt at 2.7% Ni and 2.3% Cu.

Copper Proven and Probable Mineral Reserves atNeves-Corvo increased to 29.1 Mt at 2.4% Cu from 26.1 Mt at 2.7% Cu reportedas of June 30, 2016, despite mining depletion.Zinc Proven and ProbableMineral Reserves have increased to 30.4 Mt at 7.7% Zn from 23.4 Mt at 7.2%Zn reported as of June 30, 2016, reflecting approval of the Zinc ExpansionProject.

Total copper Measured and Indicated MineralResources at Neves-Corvo has been reduced by mining depletion and geologicalre-interpretation to stand at 61.7 Mt at 2.4% Cu compared to 70.0 Mt at 2.7%Cu reported as of June, 2016.However, the total zinc Measured andIndicated Mineral Resources remain almost unchanged at 106.5 Mt at 6.1%Zn.

At Zinkgruvan, the zinc Proven and ProbableMineral Reserves have increased to 11.9 Mt at 7.2% Zn and 2.9% Pb andcopper Proven and Probable Mineral Reserves have increased to 5.3 Mt at1.8% Cu.

The tables attached to this release summarize the Mineral Reserve and Mineral Resource estimates for each of the Company’s mines as of June 30, 2017.

About Lundin Mining

Lundin Mining is a diversified Canadian base metals mining company with operations in Chile, the United States of America, Portugal, and Sweden, primarily producing copper, nickel and zinc. In addition, Lundin Mining holds an indirect 24% equity stake in the Freeport Cobalt Oy business, which includes a cobalt refinery located in Kokkola, Finland.

This is information that Lundin Mining Corporation is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons on September 5, 2017 at 5:00 p.m. Eastern Time.

Cautionary Statement in Forward-Looking Information

Certain of the statements made and information contained in this news release (including, but not limited to, the attached “Mineral Resources and Mineral Reserves – June 30, 2017” tables and notes thereto) is “forward-looking information” within the meaning of the Canadian securities laws. Forward-looking statements include, but are not limited to, statements with respect to the estimation of Mineral Reserves and Mineral Resources, planned production increases, exploration, mine plan optimization, mine life extension, and project study and development.Forward-looking statements are subject to a variety of risks and uncertainties which could cause actual events or results to differ from those reflected in the forward-looking statements, including, without limitation, risks and uncertainties relating to foreign currency fluctuations; risks inherent in mining including environmental hazards, industrial accidents, unusual or unexpected geological formations, ground control problems and flooding; risks associated with the estimation of Mineral Resources and Reserves and the geology, grade and continuity of mineral deposits; the possibility that future exploration, development or mining results will not be consistent with the Company’s expectations; the potential for and effects of labour disputes or other unanticipated difficulties with or shortages of labour or interruptions in production; actual ore mined varying from estimates of grade, tonnage, dilution and metallurgical and other characteristics; the inherent uncertainty of production and cost estimates and the potential for unexpected costs and expenses, commodity price fluctuations; uncertain political and economic environments; changes in laws or policies, foreign taxation, delays or the inability to obtain and maintain necessary governmental permits; and other risks and uncertainties, including those described under “Risk and Uncertainties” section of the Company’s most recently filed Annual Information Form and the “Managing Risks” section of each of its Management’s Discussion and Analysis. Forward-looking information is in addition based on various assumptions including, without limitation, the expectations and beliefs of management, the assumed long term price of copper, nickel, lead and zinc; that the Company can access financing, appropriate equipment and sufficient labour and that the political environment where the Company operates will continue to support the development and operation of mining projects. Should one or more of these risks and uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described in forward-looking statements. Accordingly, there can be no assurance that forward-looking information will prove to be accurate, and so readers are advised not to place undue reliance on forward-looking statements. The Company does not undertake to update such forward-looking information unless required under applicable laws.

Cautionary Notes to Investors – Mineral Resource and Reserve Estimates

In accordance with applicable Canadian securities regulatory requirements, all Mineral Reserve and Mineral Resource estimates of the Company disclosed or incorporated by reference in this news release have been prepared in accordance with Canadian National Instrument 43-101 – Standards of Disclosure for Mineral Projects adopted by the Canadian Securities Administrators (“NI 43-101”) and are classified in accordance with the Canadian Institute of Mining Metallurgy and Petroleum’s “CIM Definition Standards for Mineral Resources and Mineral Reserves” adopted on May 10, 2014 (the “CIM Standards”).

Mineral Resources which are not Mineral Reserves do not have demonstrated economic viability. Pursuant to the CIM Standards, Mineral Resources have a higher degree of uncertainty than Mineral Reserves as to their existence as well as their economic and legal feasibility. Inferred Mineral Resources, when compared with Measured or Indicated Mineral Resources, have the least certainty as to their existence, and it cannot be assumed that all or any part of an Inferred Mineral Resource will be upgraded to an Indicated or Measured Mineral Resource as a result of continued exploration. Pursuant to NI 43-101, Inferred Mineral Resources may not form the basis of any economic analysis, including any feasibility study. Accordingly, readers are cautioned not to assume that all or any part of a Mineral Resource exists, will ever be converted into a Mineral Reserve, or is or will ever be economically or legally mineable or recovered.

To view the table “Mineral Resources and Mineral Reserves – June 30, 2017”, please click on the following link: http://media3.marketwire.com/docs/Lundin.pdf

Notes on Mineral Resource and Mineral Reserve Table

Mineral Resources and Mineral Reserve estimates are shown on a 100 percent basis for each mine. The Measured and Indicated Mineral Resources are inclusive of those Mineral Resources modified to produce the Mineral Reserves. All estimates are prepared as at June 30, 2017.

Estimates for all operations are prepared by or under the supervision of a Qualified Person as defined in National Instrument 43-101, or have been audited by independent Qualified Persons on behalf of Lundin Mining.

Mineral Reserves have been calculated using metal prices of US$2.75/lb copper, US$1.00/lb zinc, US$1.00/lb lead, US$8.00/lb nickel, US$1,000/oz gold and exchange rates of EUR/US$ 1.25, US$/SEK 7.00 and Chilean Peso/US$ 550.

Candelaria and Ojos

Open pit Mineral Resources are reported within a conceptual pit shell based on metal prices of US$3.16/lb copper and US$1,000/oz gold and are reported at a cut-off grade of 0.2% copper. Underground Mineral Resources are reported at a cut-off grade of 0.6% copper.Mineral Reserves for the open pit and underground for the Candelaria property are reported at cut-off grades of 0.28% and 0.6% copper, respectively. Underground Mineral Reserves for the Ojos del Salado property (Santos and Alcaparrosa mines) are reported at cut-off grades of 0.63% and 0.66% copper, respectively. Mineral Resources and Mineral Reserves for Candelaria and Ojos del Salado were estimated by mine technical staff at Candelaria and Ojos, respectively.Patricio Caldern, Superintendent Resource Estimation, Yerko Peralta, Open Pit Mine Engineer and Cristian Erazo, Underground Mine Engineer, each of whom is a Registered Member, Chilean Mining Commission, employed by the Candelaria mining complex and a Qualified Person as defined under NI 43-101, supervised the preparation of the Mineral Resource, open pit Mineral Reserve and underground Mineral Reserve estimates respectively, and the scientific and technical information on Candelaria contained in this news release.

For further information, refer to the Technical Report entitled Technical Report for the Candelaria Copper Mining Complex, Atacama Province, Region III, Chile dated January 17, 2017, which is available on the Company’s SEDAR profile at http://www.sedar.com.

Neves-Corvo and Semblana

The Mineral Resources are reported above cut-off grades of 1.0% for copper and 3.0% for zinc. The copper and zinc Mineral Reserves have been calculated using variable Net Smelter Return (NSR) values based on area and mining method.The NSR is calculated on a recovered payable basis taking in to account copper, lead, zinc and silver grades, metallurgical recoveries, prices and realization costs. The copper Mineral Reserves are reported above a site average cutoff grade equivalent to 1.3%. For zinc Mineral Reserves an average cutoff grade equivalent to 5.5% is used.Mineral Reserves and Mineral Resources for Neves-Corvo were estimated by the mine geology and mine engineering departments at Neves-Corvo under the guidance of David Nicholls, Technical Services Manager, Nelson Pacheco, Chief Geologist, and Fernando Cartaxo, Chief Mine Planning Engineer, each of whom is employed by the Neves-Corvo mine.Nelson Pacheco EurGeol, prepared the Neves Corvo Mineral Resource estimate and Antonio Salvador, CEng MIMMM, Group Mining Engineer, Lundin Mining, reviewed and approved the Mineral Reserve estimate, and the scientific and technical information for Neves-Corvo contained in this news release. Both are Qualified Persons as defined under NI 43-101.

The Mineral Resources at Semblana are reported above a cut-off grade of 1.0% copper.The Mineral Resource estimate contained in this news release was prepared by Graham Greenway, Pr.Sci.Nat., Group Resource Geologist, Lundin Mining, who is a Qualified Person as defined under NI 43-101.

For further information, refer to the Technical Report entitled NI 43-101 Technical Report for the Neves-Corvo Mine, Portugal dated June 23, 2017, which is available on the Company’s SEDAR profile at http://www.sedar.com.

Zinkgruvan

The zinc Mineral Resources and Mineral Reserves are reported above a site average cut-off grade of 3.7% zinc equivalent. The copper Mineral Resources and Reserves are reported above cut-off grades of 1.0% and 1.5% respectively. The zinc Mineral Reserves have been calculated using variable NSR values based on area and mining method.The NSR is calculated on a recovered payable basis taking in to account copper, lead, zinc and silver grades, metallurgical recoveries, prices and realization costs.The Zinkgruvan Mineral Resource and Mineral Reserve estimates are prepared by the mine’s geology and mine engineering department under the guidance of Anja Hagerud, Resource Manager, and Jan Klre, Mine Manager, both employed by Zinkgruvan mine.Graham Greenway, Pr.Sci.Nat., Group Resource Geologist, Lundin Mining and David Allison, CEng MIMMM, Group Mining Engineer, Lundin Mining, each of whom is a Qualified Person as defined under NI 43-101, reviewed and approved the Mineral Reserves and Mineral Resource estimates and the scientific and technical information for Zinkgruvan contained in this news release.

For further information, refer to the Technical Report entitled NI 43-101 Technical Report for the Zinkgruvan Mine, Central Sweden dated January 18, 2013, which is available on the Company’s SEDAR profile at http://www.sedar.com.

Eagle and Eagle East

The Eagle Mineral Resources and Mineral Reserves are reported above a fixed NSR cut-off of US$116/t. The Eagle East Mineral Resources and Reserves are reported above a fixed NSR cut-offs of US$142/t and US$160/t respectively. The NSR is calculated on a recovered payable basis taking in to account nickel, copper, cobalt, gold and PGM grades, metallurgical recoveries, prices and realization costs. The Eagle Mineral Resource and Mineral Reserve estimates are prepared by the mine’s geology and mine engineering department under the guidance of Robert Mahin, CPG, Chief Geologist and Josh Lam, Senior Mine Engineer, both of whom are employees of the Eagle mine. The Eagle East Mineral Resource estimate was prepared by Graham Greenway, Pr.Sci.Nat., Group Resource Geologist, Lundin Mining.Robert Mahin prepared the Eagle Mineral Resource estimate and reviewed and approved the Eagle East Mineral Resource estimate and David Allison, CEng MIMMM, Group Mining Engineer, Lundin Mining, reviewed and approved the Eagle and Eagle East Mineral Reserve estimates and the scientific and technical information on Eagle and Eagle East contained in this news release. Both are Qualified Person as defined under NI 43-101.

For further information, refer to the Technical Report entitled Technical Report on the Eagle Mine, Michigan, U.S.A. dated April 26, 2017, which is available on the Company’s SEDAR profile at http://www.sedar.com.

Mark Turner Director, Business Valuations and Investor Relations +1-416-342-5565 Sonia Tercas Senior Associate, Investor Relations +1-416-342-5583 Robert Eriksson Investor Relations Sweden +46 8 545 015 50

2017 Nasdaq, Inc. All rights reserved.

Read the original here:
Lundin Mining Announces 2017 Mineral Resource and Mineral Reserve Estimates – MarketWatch

Recommendation and review posted by simmons

STEHLIK: Thank you for smoking – Yale Daily News (blog)

Iwish more people at Yale took smoke breaks.

No, I am not a misanthrope, wishing premature death upon my classmates, nor do I long for the aesthetic of DeNiro gangster movies. I realize smoking is horrible 6 million deaths each year, with 80 percent of the disease burden falling on low and middle income countries. Who knows if my grandfather would have had a stroke last year if he hadnt smoked since 1949. And dont even get me started on the tobacco industry outright lying to people around the world and suing countries trying to pass smoking regulation. Honestly, just ask my smoker friends there is no one who professes life extension through smoking cessation as aggressively as I do.

Yet, as the stress and isolation of Yale hits me hard, I text friend after friend inviting them to meet up. And my heart sinks deeper as friend after friend politely lets me know how extremely busy they are. So I light up alone on the back porch of my Howe Street house god, I miss smokers.

None of my Yale friends smoke. Yalies are too rational for this short-term indulgence. The truth has nothing to do with rationality and everything to do with incentives. In the U.S., smoking is a stigmatized lower class habit and so putting down the cigarette is just another Canada Goose patch Yale students proudly wear. The only real smokers left at Yale are international students and dining hall workers.

Going to high school in Bosnia and Herzegovina a country that ranks 10th worldwide in cigarette consumption per capita I made some of my best friends while smoking. As much as I know that my friends will regret their tobacco habit 40 years down the road, I think there are also considerable positive externalities to this addiction.

For one, Ive never had a hard time asking my friends in Bosnia for five minutes of their time they literally needed to smoke every half-hour, so they might as well do it with me.

Smoking makes for a perfect way to meet new people. From light to ash, a cigarette takes six minutes. There is no shame about being silent with another person because smoking itself gives you a good enough occupation. It is the perfect way to get out of a party mingle hell and have an actual conversation with someone. The closest thing to a smoke break at Yale are 30-minute dining hall meals, which you must plan literally weeks in advance.

There is something liberatingly nihilistic about knowing how harmful smoking is and lighting up anyway. The cigarette in my Slovak friends hand is a raised middle finger to the idea of progress and universal betterness we toil for, 14 hours a day.

Since, apart from my two-house mates who ritually pretend to take drags from a cigarette about every two months, I know no Yale smokers. It is hard for me to say whether smoking would make us kinder to each other. Even if it did, it probably would not compensate for all the strokes, cancer and erectile dysfunction that would come with smoking. It would also not justify the inherent deception involved in nicotine addiction intensely pleasurable at first, but bland, necessary and somewhat deadly over time.

Setting up incentives so that fewer people smoke is a great achievement for the United States. Tobacco-free Yale is an excellent and important initiative and cost-free Nicotine Replacement Therapy under Yale Health coverage is surely a blessing for anyone trying to stop. But still, what would it be like here if we tried to chill out in less risky ways? I heard walks are pretty relaxing.

While Yales environment constructively discourages smoking, it unwillingly encourages overwork, perfectionism, low self-esteem and putting work ahead of friends. If only banning social climbing and status obsession was as easy as banning tobacco.

Mojmir Stehlikis a junior in Trumbull College. Contact him atmojmir.stehlik@yale.edu.

Read more here:
STEHLIK: Thank you for smoking – Yale Daily News (blog)

Recommendation and review posted by Bethany Smith

QuantumClean and ChemTrace to Exhibit at SEMICON Taiwan 2017 – Markets Insider

Validated Ultra-High Purity. Maximum Productivity.

QUAKERTOWN, Pennsylvania, Sept. 6, 2017 /PRNewswire/ –Quantum Global Technologies’ companies,QuantumCleanandChemTrace,will exhibit at SEMICON Taiwan 2017 at the Taipei Nangang Exhibition Center from September 13 – 15 (booth 1718).

Logo -https://mma.prnewswire.com/media/383596/Quantum_Global_Technologies_LLC_Logo.jpg

This year, Quantum Global Technologies unveiled the world’s most advanced semiconductor chamber parts cleaning, coating and analytical facility in Tainan.

“This plant is a ‘Smart, Lean, Clean and Green’ Center of Excellence, a first of its kind in its industry. The opening of this advanced facility is yet another milestone in our evolution. A demonstration of our continuous innovation, growth and value generation for our customers,” states Scott Nicholas President and CEO, Quantum Global Technologies, LLC.

“Our Tainan cleaning, coating and analytical testingCenter of Excellencehelps our customersREDUCE cost-of-ownership.Analytically validated ultraclean parts result inFASTER chamber recoveryandLONGER Mean Time Between Cleans. Optimized cleaning methods and proprietary recoating technologiesEXTEND part life. Fast part turnaround timesREDUCE inventory costs. We are the only firm to offer ultra-high purity chamber part cleaning validated by aCertificate of Analysisfrom an accredited laboratory,” explains Nicholas.

The Tainan site is Taiwan’s only cleaning and coating service provider with an embedded microcontamination laboratory ChemTrace.

ChemTraceis an industry-leading semiconductor laboratory that provides critical insight into microcontamination issues. “The recent laboratory opening in Tainan allows regional semiconductor industry customers direct access to our advanced laboratories for rapid turnaround and expert analysis,” explains Surjany Russell, ChemTrace’s Director of Sales.

We welcome your visit to theQuantumCleanandChemTracebooth to learn more on how our service offerings can bring improvement to your operation by solving critical process chamber manufacturing challenges.

About Quantum Global Technologies, LLC

ChemTraceandQuantumCleanare divisions of Quantum Global Technologies, LLC headquartered in suburban Philadelphia, Pennsylvania USA.

QuantumCleanis the global leader in sub-10nm outsourced process tool chamber parts cleaning and coating services, tool part life extension and process tool part optimization solutions to the semiconductor wafer fabrication, OEM and OPM industries.

Founded in 2000,QuantumCleanoperates innovativeAdvanced Technology Cleaning Centersbuilt on the premise of providing customersprocess improvement through consistently cleaner partsthat exceed industry standards. These solutions dramatically reduce our customers’ total cost-of-ownership. With 1,500 employees in 18 facilitieslocated in 8 countries,QuantumCleanprovides unsurpassed cleaning capability and convenience worldwide.quantumclean.com

For over 20 years,ChemTracehas provided independent and analytical verification of process tool chamber part cleaning effectiveness. Recognized as the leading reference analytical testing laboratory for the semiconductor, solar and related industries,ChemTracehas the solutions for FAB, OEM and OPM’s critical cleaning issues and requirements. With more than 100 employees in 5 labs located in 3 countries,ChemTraceoffers unsurpassed microcontamination analysis of tool parts, wafers and depositions, chemicals, cleanroom materials, DI water and airborne molecular contamination.chemtrace.com

Media Contacts

QuantumClean:Meg Cox, +1-215-892-9300, rel=”nofollow”>info@quantumclean.com

ChemTrace:Robin Puri, +1-503-251-0979, rel=”nofollow”>info@chemtrace.com

QuantumClean, ChemTrace, Advanced Technology Cleaning Centers, ATCC, Process Improvement through Consistently Cleaner Parts, Single Part Chemical Clean and SPCC are all registered trademarks of Quantum Global Technologies, LLC.

ACS, Atomically Clean Surfaces, Alternative TWAS, Analytical & Engineering Services, C-Coat, Cleancoat, Cleaning, Coating & Testing Center of Excellence, Environmentally Clean Process, ECP, Final Surface Finish, FSF, QGT, M-Coat, PartSmart, PT3, QualClean,Selective Deposition Removal, SDR, Service Request form, SRF, Solution Based Chemistry, TechBriefs, The Perfect Order, The Perfect Qual, The Perfect Process Transfer, Tight-Coat, V-Clean, VeriClean, Waterless Acid, Y-Coat, Z-Coat, Smart, Lean, Clean and Green, Center of Excellence and Validated Ultra-High Purity. Maximum Productivity are all trademarks of Quantum Global Technologies, LLC.

SOURCE QuantumClean

More here:
QuantumClean and ChemTrace to Exhibit at SEMICON Taiwan 2017 – Markets Insider

Recommendation and review posted by Bethany Smith

Osteoporosis cure? Woman reveals THIS treatment has REVERSED her symptoms – Express.co.uk

Although a fracture is the first sign of osteoporosis, some older people develop the characteristic stooped – bent forward – posture, which can cause people to lose height.

Height is lost as the bone crumbles and vertebrae collapses, and the chest and abdomen capacity decreases, sometimes resulting in difficulty breathing as the ribs end up touching the pelvic bone.

When the bones in the spine have fractured, it can be difficult to support the weight of the body.

However, now a London-based clinic has revealed that a treatment programme can reverse some of the height lost through the common age-related bone disorder.

The London Osteoporosis Clinic uses a combination of drug-therapy, non-drug treatments and lifestyle approaches to help patients.

Anne Torry, a 75-year-old bookkeeper, said her height increased by 3cm following treatment at the clinic.

Unbeknownst to me, I actually managed to fracture two discs in my back getting out of the car in a hurry one day; after dealing with the discomfort and niggling pain for a while, my GP organised an x-ray which showed the fractures, said Anne.

It came as somewhat of a surprise, particularly when my GP suggested that I may have osteoporosis.

I waited patiently for the results, not for a minute thinking that they would be positive.

I was again taken aback when I was told that the fractures were due to osteoporosis and that I would benefit from undergoing treatment.

Anne is among a number of patients at London Osteoporosis Clinic whose treatment programme included the parathyroid hormone Teriparatide, one of the only drugs that can not onlyslow down the progression of osteoporosis, but also help to grow new bone.

Annes bone density is showing an improvement of over 10 per cent per year since starting treatment.

My GP referred me to the London Osteoporosis Clinic, and I met with Dr Taher Mahmud, she said. From the outset, he reassured me and was certain that he could help me.

Even so, when I discovered that I had regained the three centimetres in height that Id lost to osteoporosis, I was amazed. It was the last thing I was expecting.

My day to day life has improved through the treatment programme, and I am now able to live a reasonably comfortable life, managing jobs that may before have been a little more difficult.

The biggest surprise, however, was definitely the increase in my height!

Following a consultation with Dr Mahmud, a diagnosis will be made by examining the results of a bone density (DEXA) scan.

Depending on the stage and severity of osteoporosis, a treatment plan will be put in place, which can range from advice on lifestyle, such as giving up smoking and diet to several drug options, including an 18 to 24 month course of daily injections, prescribed to stimulate cells that create new bone, increasing bone density and replace height lost through the deterioration of bone.

The clinic was co-founded by Dr Taher Mahmud whose mother had osteoporosis. Dr Mahmud co-founded London Osteoporosis Clinic with former General Medical Council president, Sir Graeme Catto.

Initially we thought that Annes increase in height was an anomaly; we didnt expect it to be a regular occurrence in our patients, said Dr Mahmud.

However, in the last week alone, I have seen three further patients who have gained between one and three centimetres in height over the course of one to six months.

My vision was to create a clinic that deals with osteoporosis holistically, and that intervenes early with regards to diagnosis and treatment of this potentially debilitating condition.

Dr Mahmud said more than 8 million osteoporotic fractures occur worldwide- which equates to one every three seconds.

It is not a well-known fact that osteoporosis can be reversed, bone density can be increased, height can be restored and life can go on.

OSTEOPOROSIS RISK FACTORS REVEALED

Originally posted here:
Osteoporosis cure? Woman reveals THIS treatment has REVERSED her symptoms – Express.co.uk

Recommendation and review posted by simmons

4 reasons you should limit your kid’s screen exposure – TheHealthSite

If you are travelling by bus or sitting at a doctors clinic, you will see kids playing games on mobiles. The other day I saw my cousins kid spending around 2 hours just sitting on a couch watching videos and playing on phone. If the phone is not available then spending time on acomputer or videos games or television is what most kids resort to. Going outdoors to play is a far fetched idea. One reason why constant exposure to screen or screen-based activities is a really bad idea is that it can impair the brain function and health. Dr Jyoti Chawla, Senior Consultant Paediatrics, Paras Panchkula says that reducing screen-based activities can help to rebalance brain chemistry and improve its function. It is important for children in the modern age to have controlled exposure to screens, in particular through video games, television and now mobile phones. Here are a few reasons why reducing screen based activities in kids is good for the brain health. Here are4 tips to stop your child from watching too much TV.

1. Ensures healthy hormone balance:It is seen the spending time on screen or doing related activities trigger dopamine release, which is the hormone majorly responsible for activating addiction pathways. However, reducing the screen time can help balance the hormones melatonin, which is a hormone essential for good health and well-being. Melatonin also gets converted to serotonin, a hormone necessary for calmness, a sense of well-being, and bonding, and it influences mood and social behaviour.

2. Improves blood flow to the frontal lobe: Critical thinking, creative activities, and sports improve frontal lobe blood flow, whereas screen activities tend to localize blood flow to the more primitive areas of the brain. This is not only bad for adultsbut also for children. These shifts in the blood flow can be devastating over time and may impact the development of the brain permanently. Read about whats the right age to give your child a smartphone?

3. Reduces stress hormones: Screen activities are associated with the stress response. This means fight-or-flight hormones are released in the short term, and cortisol, which is known as the stress hormone, is increased over time. Both of these hormonal trends are linked to cognitive, mood and behavioural issues as well as poor physical health.

4. Reduces overstimulation: The brain is not meant to be bombarded with unnatural visual stimulation such as overly bright and intense colors, rapidly shifting scenes, excessive movement, plus the brightness of the screen itself. Moreover, it is also not meant to process man-made electromagnetic fields, which is the case when you spend most of the time on screen. Hence, reducing thescreen exposure can help you to lower the overstimulation to the brain and improve your overall well being.

Also read about reasons why your child is not sleeping tonight!

Image Source: Shutterstock

Published: September 4, 2017 3:00 pm

The rest is here:
4 reasons you should limit your kid’s screen exposure – TheHealthSite

Recommendation and review posted by simmons

Houghton International gains EASA accreditation – BQ Live

Founded in 1984, Houghton International has expanded over the last 30 years into a multi-million pound, multinational business. Specialising in innovation in the repair, maintenance and life extension of rotating electrical machines, the company has grown from originally serving one customer to now working with over 200 customers globally in a broad range of sectors including power generation, renewables, industrial, oil & gas, marine and rail.

Having opened a large machine repair shop and invested over 300,000 in plant and machinery over the past year to improve performance and keep up with demand,EASA accreditation means that the companyhas successfully demonstrated that it complies with EASA AR100 and follows the prescribed good practices to consistently deliver quality electromechanical repairs that maintain or improve AC electric motor efficiency and reliability.

Michael Mitten, CEO of Houghton International, commented: With over 30 years experience in the repair, maintenance and life extension of electrical rotating machines, becoming an EASA accredited service centre reaffirms our commitment to delivering high quality repairs to our UK and global customer base.

EASA is the worlds leading authority in electro mechanical repair and maintenance, and represents the highest standard and best practice in this industry. Our customers can be assured that any work carried out in our shop meets with or exceeds these standards and be confident in our service.

Linda J. Raynes, CAE, EASA president and CEO said: “This achievement by Houghton International affirms the company’s commitment to excellence. EASA’s accreditation program offers external validation that the company adheres to good practices by submitting to an independent, third-party audit.”

EASA is the electro-mechanical authority; an international trade organisation consisting of more than 1,800 electromechanical sales and service firms in 59 countries. EASA member companies provide repair, service, and sales for the operation and maintenance of electric motors, generators, drives, controls, pumps and other electromechanical equipment.

See more here:
Houghton International gains EASA accreditation – BQ Live

Recommendation and review posted by Bethany Smith

U of R hosts stem cell swabbing initiative to help save lives through national database – Globalnews.ca

At just four-years-old, Erica Honoways son has gone through more than most people will experience in a lifetime.

In February 2016, the family received devastating news, her son Lincoln had been diagnosed with bone marrow failure. He was just three years old at the time.

Lincoln needed a bone marrow transplant, and doctors were only able to find two matches in the entire world. The first donor fell through, so Lincoln was left with only one option.

It was terrifying. We didnt know what we were dealing with, Honoway said. We didnt know what the chances were they would find a match for him. Even if they did, we didnt know if he would make it through the transplant, so it was the scariest experience of our lives.

After the blood transfusions, chemotherapy, radiation and bone marrow transplant, Lincoln is now a happy and active four year old, all thanks to an unknown hero.

This person has just been our angel, Honoway said. We love her and we dont even know her. We say her We have a feeling its a woman but we dont know anything about this person. We dont know where in the world they live, we dont know if its a man or a woman, we dont know anything. But all we know is that they are our hero.

Honoway added that they must wait a minimum of two years before they can meet the donor.

Lincolns successful transplant was the reason Honoway and her family were supporting the University of Reginas Get Swabbed event on Monday, to encourage students between the ages of 17 and 35 to get their cheeks swabbed and enter a national stem call database.

I heard about Erica and Lincoln and I just thought it was amazing how someone just saved his life, and she doesnt even know who he is or who she is, I just think its amazing, U of R Stem Cell Club president Sylvia Okonofua said. I felt like if I take up this initiative and actually run drives where people [can get] on the stem cell registry, [it can] help save a life someday.

Getting students involved and realizing their impact of their involvement through something like this was one of the main goals, U of R student engagement co-ordinator Doug OBrien said. Another goal of having todays Get Swabbed initiative was obviously to support the stem cell database for Canada and through the One Match program.

Approximately 80 students took part in Mondays Get Swabbed event, and organizers are hoping to increase that number for the next event on Sept. 14.

Its a simple way to help save a life.

I hope people realize that they have the opportunity to save someones life, imagine what that would feel like, Honoway said. Youd get to know forever that you saved another humans life. Its pretty special.

2017Global News, a division of Corus Entertainment Inc.

See the original post here:
U of R hosts stem cell swabbing initiative to help save lives through national database – Globalnews.ca

Recommendation and review posted by Bethany Smith

Chemo-boosting drug discovered for leukaemia – Drug Target Review – Drug Target Review

Drugs developed to treat heart and blood vessel problems could be used to treat leukaemia

Drugs developed to treat heart and blood vessel problems could be used in combination with chemotherapy to treat an aggressive form of adult leukaemia.

Researchers at the Francis Crick Institute, Kings College London and Barts Cancer Institute discovered that acute myeloid leukaemia (AML) causes bone marrow to leak blood, preventing chemotherapy from being delivered properly.

Drugs that reversed bone marrow leakiness boosted the effect of chemotherapy in mice and human tissue, providing a possible new combination therapy for AML patients.

To study how AML affects bone marrow, the researchers injected mice with bone marrow from AML patients. Later, they compared their bone marrow with healthy mice using a technique called intravital microscopy that allows you to see biological processes in live animals. They found that pre-loaded fluorescent dyes leaked out of the bone marrow blood vessels in AML mice, but not healthy mice.

Next, the team tried to understand what caused the bone marrow in AML mice to become leaky by studying molecular changes in the cells lining the blood vessels. They found that they were oxygen-starved compared to healthy mice, likely because AML cells use up a lot of oxygen in the surrounding tissue. In response to a reduction in oxygen, there was an increase in nitric oxide (NO) production a molecule that usually alerts the body to areas of low oxygen.

As NO is a muscle relaxant, the team suspected that it might be causing bone marrow leakiness by loosening the tight seams between cells, allowing blood to escape through the gaps. By blocking the production of NO using drugs, the team were able to restore bone marrow blood vessels in AML mice, preventing blood from leaking out. Mice given NO blockers in combination with chemotherapy had much slower leukaemia progression and stayed in remission much longer than mice given chemotherapy alone.

When the vessels are leaky, bone marrow blood flow becomes irregular and leukaemia cells can easily find places to hide and escape chemotherapy drugs, said researcher Dr Diana Passaro. Leaky vessels also prevent oxygen reaching parts of the bone marrow, which contributes to more NO production and leakiness.

By restoring normal blood flow with NO blockers, we ensure that chemotherapy actually reaches the leukaemia cells, so that therapy works properly, she added.

In addition to ensuring that chemotherapy drugs reach their targets, the team also found that NO blockers boosted the number of stem cells in the bone marrow. This may also improve treatment outcomes by helping healthy cells to out-compete cancerous cells.

The team also found that bone marrow biopsies from AML patients had higher NO levels than those from healthy donors, and failure to reduce NO levels was associated with chemotherapy failure.

Our findings suggest that it might be possible to predict how well people with AML will respond to chemotherapy, said Dr Dominique Bonnet, senior author of the paper and Group Leader at the Francis Crick Institute.

Weve uncovered a biological marker for this type of leukaemia as well as a possible drug target. The next step will be clinical trials to see if NO blockers can help AML patients as much as our pre-clinical experiments suggest.

We found that the cancer was damaging the walls of blood vessels responsible for delivering oxygen, nutrients, and chemotherapy. When we used drugs to stop the leaks in mice, we were able to kill the cancer using conventional chemotherapy, said Dr Passaro. As the drugs are already in clinical trials for other conditions, it is hoped that they could be given the green light for AML patients in the future.

See original here:
Chemo-boosting drug discovered for leukaemia – Drug Target Review – Drug Target Review

Recommendation and review posted by simmons

Bone marrow transplant on record run in SCB Medical College and Hospital at Cuttack – The New Indian Express

Bishnupriya Nayak at BMT unit after bone marrow transplantation | Express

BHUBANESWAR: The Haematology Department of SCB Medical College and Hospital (SCBMCH) at Cuttack has notched up a record of sorts and achieved a new milestone in the country by performing 50 bone marrow transplantations in just over three years.

The special Bone Marrow Transplant (BMT) unit started in February 2014 has conducted its 50th procedure on Bishnupriya Nayak (40), a cancer patient from Koelnagar in Rourkela, on Sunday.Head of the department Prof Rabindra Kumar Jena said it is a significant achievement as SCBMCH having all state-of-the-art facilities is the only State-run hospital in the country to complete 50 cases and provide BMT services completely free of cost.

We have a great record of survival rate of patients than other such units elsewhere in the country. Of 50 cases conducted so far, 47 patients are healthy and doing normal activities. Two died due to infection within a month after BMT procedure, another succumbed to brain stroke (not related to BMT or disease) on 178th day, he said.

The BMT unit at SCBMCH has also established a few international and national distinctions. The eldest transplant conducted so far in Asia and Europe region belonged to the unit. Zabar Khan (74), who was suffering from multiple myeloma (a type of blood cancer) is doing fine after the procedure was performed.Similarly, five patients, aged over 65, have been transplanted successfully which is first-of-its-kind in India, Asia and Europe. The first BMT, also known as stem cell transplant, was performed on Sakuntala Sahoo (54) from Kendrapara district on April 23, 2014.

The unit has also mobilised the stem cell adequately in many complicated blood cancer patients who had very low stem cell blood level of 8.7 per micro litre, besides multiple chemotherapy treated cases and successfully performed BMT procedures.

Stating that the priority is being given on adequate stem cell mobilization, collection and engraftment (proper functioning of new bone marrow graft), Prof Jena said the unit is going to start allogenic BMT soon.

We have been doing autologous transplants so far. Our next plan is to start allogenic transplants. We are poised to take complicated cancer patients for BMT. Besides, plans are afoot to expand the unit to a 20-room ward to accommodate huge waiting lists patients, including thalassemia, sickle sell disease and various cancer patients, he added.

Read the original here:
Bone marrow transplant on record run in SCB Medical College and Hospital at Cuttack – The New Indian Express

Recommendation and review posted by Bethany Smith

Irish researcher bags 150000 to make 3D-printed knee implant – Siliconrepublic.com

Irish researcher Prof Daniel Kelly has secured 150,000 in funding to develop a novel implant for treating cartilage damage.

As a recipient of one of the European Research Councils Proof of Concept grants, Prof Daniel Kelly will now spend the next 18 months developing his 3D-printed project entitled Anchor.

Using the 150,000, Kelly will look to develop and commercialise his new medicinal product for cartilage regeneration, employing a postdoctoral researcher to help.

Those active in many sports would be familiar with cartilage damage as a result of injury, of which many cases occur in the knee joint. If left untreated, it can lead to difficulties such as osteoarthritis (OA).

OA can be a debilitating condition, with 80pc of those over the age of 60 experiencing limitations in movement and 25pc saying they cannot perform their major daily activities, according to the World Health Organisation.

Kellys product uses 3D-printed, biodegradable polymer components to make a scaffold, which acts as a template to guide the growth of new tissue by recruiting endogenous bone marrow derived from stem cells.

This, Kelly believes, gives it a competitive edge over similar implants, as standard ones are designed with a finite lifespan, making them unsuitable for younger patients with OA.

Kelly, a principal investigator at AMBER the Trinity College Dublin materials science research centre explained why it could be a major breakthrough for other conditions, such as arthritis.

Our 3D-printed polymer posts will anchor the implant into the bone and will be porous to stimulate the migration of stem cells from the bone marrow into the body of the scaffold, he said.

While various scaffolds like this have been available for some time, they have had limited success, partly because scaffolds need to be anchored securely due to the high forces experienced within the joint. Our 3D-printed posts overcome this problem.

Prior to Anchor, Kelly had worked on this technology in previous projects, such as the ERC-funded StemRepair project to develop a range of porous cartilage-derived scaffolds, and JointPrint.

Read this article:
Irish researcher bags 150000 to make 3D-printed knee implant – Siliconrepublic.com

Recommendation and review posted by sam

How animal genes go into battle to dominate their offspring – Gears Of Biz

Authors

Director of the Ecology Institute, Universidad Nacional Autnoma de Mxico (UNAM)

Professor of Evolutionary Biology and Speciation, University of St Andrews

University of St Andrews

The burdens of becoming parents are often shared unequally between male and female animals. This is particularly true of species that give birth to live young, where male duties such as defending the breeding territory and building dens or nests rarely compare with the ordeals of pregnancy and labour.

You might have thought that animals just accept this imbalance and get on with it. But actually, they compete over how much each parent contributes. This isnt like the competition to win a mate, with locking horns or displays of plumage. Instead this remarkable battle takes place at the level of the genes.

It now appears it may have evolved very early in animal evolution, perhaps among the first child-bearing animals. What is more, it may even help to explain why animals diversified into different lineages.

One arena in which this battle plays out is over the size of offspring. In principle its in both a mothers and fathers interests to produce bigger newborns, since they are more likely to prevail in the struggle for food and survival.

Yet live-bearing females are more likely to die giving birth to larger offspring or become unable to reproduce again. Their mates neednt care unless they are likely to sire more broods together, as with humans and certain gibbons, wolves and mice. Otherwise, the males only concern is that their mate invests as much as possible in the offspring they produce together.

This common conflict of interests manifests itself in various ways in nature. Males often desert pregnant females from birds to humans, for example thereby leaving them with the burden of bringing up the young. More rarely, in some normally biparental species females desert males. We see this in some beetles, for example.

The genetic battle mentioned previously is another manifestation of this conflict. The males of many species can manipulate the genes that they pass on to their offspring so that they induce extra growth at the expense of the mother. As with desertion, this effectively hands the female a greater share of the child-bearing burden than is in her interests.

It works as follows. When an embryo grows inside its mother, it consumes resources from her, signalling its metabolic needs along the way. These signals are influenced by certain hormones which either come from the growth genes of the mother or father. The males manipulate the females to deliver more resources by increasing the extent to which these hormones are produced through a chemical modification of their growth genes during sperm formation.

Females have evolved mechanisms to resist this. They can, for instance, pass on to their offspring what is known as a silenced copy of their own growth gene. This can counterbalance the male genes influence by making the embryo grow less than it otherwise would.

This battle is far less prevalent in truly monogamous species, including humans. This goes back to the fact that it becomes less genetically necessary where the two parents have a common interest in the female producing more offspring in future.

British microbiologist David Haig first proposed in 2003 that this battle was more likely in organisms where one sex disproportionately contributes to the offspring, such as live-bearing species, particularly polygamous ones. This was used to explain the puzzling size of the offspring of crosses between oldfield mice and deer mice.

Separately, these species produce similar sized offspring. Yet crosses between male deer mice and female oldfield mice produce offspring that are larger, while the offspring from female deer mice and oldfield males are smaller. Oldfield mice are monogamous while deer mice are polyandrous, meaning one female mates with several males.

Mimicking nature by artificially manipulating a growth gene called igf2, researchers showed that these smaller and larger offspring were due to genetics. In further support of the theory, placental mammals and marsupials including kangaroos and opossums have since been found to have signs of female resistance to such male manipulation.

How early did this mechanism evolve? Researchers have previously suggested it arose in live-born mammals, and would therefore be absent in egg-laying mammals such as the platypus and other vertibrates.

But that raises questions about all the reptiles, amphibians and fish which produce live young, since the same genetic manipulation would equally be in their males interests. To see if it was present, we looked at a Mexican fish called the amarillo or dark-edged splitfin (see lead image).

Along with co-researchers Yolitzi Saldvar and Jean Philippe Vielle Calzada, we crossed males and females from two distant populations of these fish, since they would not have evolved mechanisms which cancel one another out in the way that a single population is likely to have. Sure enough, the size of the embryos was influenced by the specific combination of father and mother. We found signs of male manipulation and probable resistance from the females.

Though based on a small sample size, this suggests that these mechanisms evolved much earlier than previously believed: fish split from other vertebrates some 200m years before live-bearing mammals appeared, dating back about 370m years in total. Whether it comes from a single evolution or from several in different lineages, we cannot yet tell.

One consequence of these genetic battles is the effect on reproductive compatibility within a species. The genetic mutations aimed at manipulating offspring that take place among males and females within a certain group of a species are like a sort of arms race. The genes continually adapt and counter-adapt to one another to try and further their reproductive interests.

If they then mate with an animal from a different group of the same species, their genetic mutations can have made them sufficiently unmatched over time that they are unable to reproduce thus they are now two species. If this started happening much earlier in evolution than was previously thought, it is likely to have influenced how different groups of live-born animals diverged, including lizards, sharks and mammals. From little acorns, these are the kinds of big oak trees that can grow.

This article was originally published on The Conversation. Read the original article.

Source

Go here to see the original:
How animal genes go into battle to dominate their offspring – Gears Of Biz

Recommendation and review posted by Bethany Smith

A Fourth-Generation DNA Base Editor Could Replace CRISPR – Futurism

CRISPR: The Next Generation

The latest news in genetic science has been dominated by the CRISPR/Cas9 technique over the past fiveyears. But a new fourth-generation DNA base editor could see CRISPR dethroned, according to a recent study published in Science Advances.

The fourth-generation base editor a tool used to modify the building blocks of genetic code, only now with an inhibitor added to protect DNA from accidental changes heightens editing accuracy and reduces unintentional DNA changes, which occur with current base-editing technologies.

DNA is a series of base pairs, or nucleotides: adenine, thymine, guanine and cytosine, called A-T-G-C for short. When CRISPR converts a C:G base pair to a T:A pair, sometimes it inadvertently changes the C:G base pair to a G:C or A:T base pair. Thismight seem like an insignificant mess of letters, but on the genetic level, even a single mistaken nucleotide can have devastating consequences for an organism.

Approximately two-thirds of known human genetic variants associated with disease are point mutations, said study co-author David R. Liu, Harvard University Professor of Chemistry and Chemical Biology and Howard Hughes Medical Institute Investigator, in an email interview with Futurism.The fourth-generation base editors to my knowledge are the most effective forms of these molecular machines that can directly correct certain types of point mutations.

Liu, co-author Alexis Komor, and their colleagues found that the number of undesired editing products depends on the level of a cutting enzyme called uracil N-glycosylase (UNG). Uracil is one of the four base pairs found in RNA, which is involved in the process of transcribing DNA so that its code is physically expressed by the organism.

Mechanistically, it made sense that [this]was leading to the undesired products we would occasionally observe, Liu explained. The teamhad a hunch that UNG, which initiates base excision repair at uracils, might be the culprit. Indeed, when we performed base editing in cells lacking UNG, essentially all undesired product formation went away.

Komoret al. then designed a fourth-generation base editor combined with an inhibitor, called BE4, which blocks UNG from cutting and altering DNA inadvertently. BE4 shuts down the cellular troublemaker (UNG) more effectively than our previous base editors, which results in higher efficiency of C to T base editing, and also fewer undesired products, said Liu.

Using BE4 formed with the bacteriaStreptococcus pyogenes, this base editing procedure increased the efficiency of swapping C:G to T:A by 50 percent, while halving the frequency of undesired byproducts. Click to View Full Infographic

This comes at a time when the number of incredible things CRISPR is doing extends beyond the medical field: into ecology, with the possibility of artificially designing algae to create a more efficient biofuel, and national security, with the U.S. Advanced Research Projects Agency (DARPA) investing $65 million in a project called Safe Genes.The DARPA Safe Genes program is very forward-thinking and focused on important issues including safest practices for genome editing, as well as helping to advance these technologies to realize their full potential, commented Liu.

Ultimately, the optimum balance lies in protecting the public with restrictions on gene editing technology, but not implementing so many that it decreases the number and diversity of efforts to use these technologies for the public good, Liu said.

For a nominal charge, Lius team has made the base editor available ona nonprofit genetic repository called Addgene: We definitely want the scientific community to use these tools.

Read the original post:
A Fourth-Generation DNA Base Editor Could Replace CRISPR – Futurism

Recommendation and review posted by simmons

Workshop Next Week On Public Interest And CRISPR Gene Editing, CAR T Cancer Treatment – Intellectual Property Watch

Experts at a one-day workshop in Washington DC next week will discuss public interest aspects of patents and two breakthrough new medical technologies related to gene editing (CRISPR) and cancer treatment (CAR T).

The 15 September event, entitled, Patents, the Public Interest and Two New Medical Technologies: CRISPR and CAR T, will feature a unique mix of key health advocates, academics, licensing and standards experts, congressional staff and others.

A live webcast on YouTube will be available here.

Event moderators include William New of Intellectual Property Watch and Sarah Karlin-Smith of Politico.

The full KEI event announcement is reprinted below:

Workshop: Patents, the Public Interest and Two New Medical Technologies: Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR), Chimeric Antigen Receptors (CAR) technologiesOn September 15th, 2017, Knowledge Ecology International will be hosting a workshop on: Patents, the Public Interest and Two New Medical Technologies: CRISPR and CAR T.

CRISPR related inventions include breakthrough technologies to modify genes, which have broad applications for innovations in medicine, agriculture and other fields.

CAR T therapies are an exciting new approach to treating cancer and other diseases, including previously incurable cancers.

Both technologies were developed with significant funding from the U.S. federal government.

There are controversies over the licensing of several CRISPR related inventions, and over the pricing of new CAR Treatments, including most recently the decision by Novartis to charge $475,000 for Kymriah, a CAR T treatment for leukemia.

The workshop will bring feature a diverse group of experts and stakeholders to discuss the public policy challenges appropriate governance of CRISPR and CAR Ts intellectual property.

Date: Friday, September 15, 2017Location: Kaiser Permanente Center for Total Health, 700 Second St. NE (near Union Station), Washington, DC 20002

To Register: use this form.

A PDF version of the program is available here.

Related

See original here:
Workshop Next Week On Public Interest And CRISPR Gene Editing, CAR T Cancer Treatment – Intellectual Property Watch

Recommendation and review posted by sam

New genetic testing lab development to improve DNA test turnaround – Sheep Central

Processing time for sheep DNA tests is set to improve through Neogens new genomic testing laboratory in Queensland.

AUSTRALIAN sheep DNA testing turnaround times are expected to be more reliable and up to 40 percent faster with Neogen Corporations decision to establish a genomic testing laboratory in Queensland.

GeneSeek Australasia, a wholly owned subsidiary of United States-based parent company Neogen, has acquired the assets of the Animal Genetics Laboratory, based at the Gatton campus of the University of Queensland.

The Neogen facility in Australia will be its fourth animal genomics laboratory, joining locations in the US, Scotland, and Brazil.

Chief executive officer of the Cooperative Research Centre for Sheep Industry Innovation (Sheep CRC) Professor James Rower expected reliable turnaround times for DNA could be reduced from four to three weeks.

Todays announcement is a major development which will help consolidate the use of DNA technologies and support accelerated genetic improvement in our flocks.

The Cooperative Research Centre for Sheep Industry Innovation (Sheep CRC) has led the development of DNA testing within the Australian sheep industry and has worked in collaboration with Neogens GeneSeek laboratories since the start of the Information Nucleus program in 2007.

GeneSeek has always provided competitive pricing and excellent quality control but until now all tests had to be shipped to the US for processing, Sheep CRC chief executive James Rowe said.

While the range of DNA test products we have developed has proven to be immensely valuable to sheep breeders, the turnaround time from taking blood samples to receiving results has been the biggest single factor limiting wider uptake of genomic technologies within the Australian sheep industry.

Professor Rowe didnt expect the development would change the price of DNA testing initially.

The real story is that we wont need to send our samples to the United States in the future, which is one step that has been variable and quite frustrating.

Every now and then you get a batch that is held up in US Customs or goes walkabout with the courier system, and when that happens it pushes our turnaround time out to about 10 weeks.

Prof. Rowe said the new lab would result in faster and more consistent turnaround time and combined with the new GeneSeek technical platform would also mean fewer repeat analyses.

At the moment we are operating pretty much on a 4-5 week turnaround, unless you get a glitch, which throws everyone into turmoil, he said.

But Professor Rowe said there would be a transition period while Neogens new Queensland laboratory is set up, but within six months, DNA test turnaround times could drop to three weeks.

Thats a game-changer.

Quicker turnaround would be particularly valuable for terminal ram breeders wanting to make earlier selection decisions after taking weaning weight, muscle and fat scan measurements, he said.

Neogens vice president of corporate development and cirector of GeneSeek AustralAsia, Dr Jason Lilly, said that as Neogens business in Australia had grown, the company had recognized the importance of improving its presence in the local market and its service to strategic partners such as the Sheep CRC.

Combining AGLs complementary expertise and local support with GeneSeeks animal genomic capabilities, will provide Australian sheep producers with the utmost in local service, turnaround time, and technical support, Dr Lilly said.

The lab will feature the latest equipment and will be compatible with the recent developments in the parentage and 15k multi-trait genotyping tests for the Australian sheep industry.

This will mean that breeders will be able to plan their genotyping around the best possible combination of parentage and multi-trait genotyping testing to minimise the costs of double testing and maximise the information from multi-trait genomic predictions, Prof. Rowe said.

GeneSeek has always provided excellent technical support in the design and development of the Sheep CRCs DNA testing systems and being based in Australia is likely to further enhance what has been a very productive working relationship.

Read more here:
New genetic testing lab development to improve DNA test turnaround – Sheep Central

Recommendation and review posted by sam

Genetic testing may benefit this population – ModernMedicine

In the Ashkenazi Jewish population, the mutation profile ofBRCA1andBRCA2is distinctive, with three ancient founder mutations in these two genes. Combined, these three mutations are responsible for 10% of invasive breast cancer among Ashkenazi Jewish women.

The relatively high frequency of the Ashkenazi Jewish founder mutations inBRCA1 andBRCA2has enabled the effective use of cancer genetics services by Jewish women, according to research published online July 20, 2017, in JAMA Oncology.

For Ashkenazi Jewish patients with breast cancer who do not carry one of these three founder mutations, the chance of carrying some other pathogenic mutation inBRCA1orBRCA2, or a pathogenic mutation in a different breast cancer gene, is not known. This information, however, would be valuable to patients and their families for cancer prevention and treatment.

King

A group of researchers, led by Mary-Claire King, PhD, Department of Medicine, University of Washington in Seattle, conducted a study to determine the frequency of cancer-predisposing mutations other than theBRCA1andBRCA2founder mutations among patients of Ashkenazi Jewish ancestry with breast cancer.

Should Ashkenazi Jewish women with breast or ovarian cancer who have negative results for the three founder mutations obtain complete sequencing ofBRCA1andBRCA2so as not to miss some other mutation? Should these patients also be tested for mutations in other breast cancer genes?

We addressed these questions by sequencing all known breast and ovarian cancer genes in genomic DNA, which was provided by participants of the New York Breast Cancer Study (NYBCS), a longstanding cohort of Ashkenazi Jewish women with a primary diagnosis of invasive breast cancer, the authors said.

The result, they said, is that Ashkenazi Jewish patients with breast cancer can benefit from genetic testing for all breast cancer genes. Comprehensive sequencing would provide complete relevant genetic information.

See the original post here:
Genetic testing may benefit this population – ModernMedicine

Recommendation and review posted by Bethany Smith

This Company Freezes Your Body So That You Could One Day Be Resurrected – Billionaire BLLNR | Singapore (registration)

An estimated 2,500 bodies around the world have been frozen in the hope of some future resurrection.

Robert Ettinger, the father of cryogenics, who introduced the concept in 1962.

If you have around US$90,000 to spare and are of a gambling disposition, perhaps your final journey should be to Australia. A company called Southern Cryonics is looking to open a facility in New South Wales this year that will allow its customers to freeze their bodies after death in the hope of one day being resurrected. If it goes ahead, it will make Australia only the third country, after the US and Russia, where such a service is available.

But, especially for those of a futurist bent perhaps, its as valid a thing to do with ones body as burial or cremation. Last year, a terminally ill 14-year-old girl in the UK became the first and only child so far to undergo the cryonic process. This is technically not freezing but vitrification, in which the body is treated with chemicals and chilled to super-cold temperatures so that molecules are locked in place and a solid is formed. An estimated 2,500 bodies around the world are now stored in this condition.

Supporters concede that the technology to revive the infinitely complex interactions between those molecules may never exist, but are nonetheless hopeful, pointing to shifting conceptions of what irreversible death actually is. If, for example, cessation of a heartbeat used to define it, now hearts can be re-started todays corpse may be tomorrows patient. They point to experiments such as that announced last year by 21st Century Medicine, which claimed to have successfully vitrified and recovered an entire mammalian brain for the first time, with the thawed rabbits brain found to have all of its synapses, cell membranes and intracellular structures intact.

Its not just cryonics. Stem-cell research, nano-tech, cloning, the science just keeps plugging away towards a future [of reanimating] that may or may not come to exist, says an upfront Dennis Kowalski, president of the Michigan-based Cryonics Institute. His company was launched just over 40 years ago to provide cryostasis services. Lots of things considered impossible not long ago are possible today, so we just dont know how cryonics will work out. For people who use the service its really a case of theres nothing to lose.

Naturally, not everyone is hopeful that such processes will ever work out for those in the chiller. The problem with cryonics is that the perception of it is largely shaped by companies offering a service based on something completely unproven, says Joo Pedro De Magalhes, biologist and principal investigator into life extension at the University of Liverpool, UK, and co-founder of the UK Cryonics and Cryopreservation Network. Youre talking about a fairly eccentric procedure that only a few people have signed up to and into which little reported research is being done. That said, I think the people providing these services do believe theres a chance it may work one day, although I would have to say theyre optimistic.

But this is not to say that living longer wont, in time, prove possible as a result of some other method; just that arguably this is more likely to be based around preserving a life that has not experienced death, rather than the promise of reanimating one after its demise. The chasm between the two is all the more pronounced given neurosciences still scant ideas as to what consciousness or mind is, let alone how it might be saved and rebooted; would the warmed and reanimated you be the you that died, or a mere simulacrum? Your body may well not be the same: many of those opting for cryo-preservation go for the freezing of just their brains.

Certainly while cryonics specifically may remain a largely unexplored field, Google is now investing in anti-ageing science, an area that, as De Magalhes puts it, now has fewer crackpots and more reputable scientists working in it, with stronger science behind it too. Indeed, as Yuval Noah Harari argues in his best-selling book Homo Deus, humanisms status as contemporary societys new religion of choice, combined with technological advances, makes some form of greatly extended lifespan inevitable for some generation to come. Whether this will be by melding man and machine, by genetic manipulation, by a form of existence in cyberspace or some other fix can only be speculated at, but everything about our civilisations recent development points to it becoming a reality.

Advances in medicine, after all, have greatly extended average longevity over the last century alone. With this has come a shift in perspective that sees death less as the natural end point to a life so much as a process of disease that could, and perhaps should, be tackled like any other disease that threatens existence. De Magalhes points out that for many working in the field it is less about the pursuit of immortality as of improved health.

After all, its not self-evident that we all want to live forever, and there are philosophical arguments for the idea that death is good, that its necessary to appreciate life, he says. But it is self-evident that nobody wants Alzheimers, for example. If you focus on retarding the problems of ageing then inevitably were going to live longer. The longevity we have now isnt normal; its already better than what we had not long ago. Extrapolate that to the future and in a century the length of time we live now might be considered pretty bad. One can envisage a time when we might live, if not forever, then perhaps thousands of years so much longer than we live now that it might feel like forever.

That, naturally, would bring with it profound changes to the way in which we perceive ourselves and to how the world operates and all the more so if living considerably longer became a possibility faster than society was able to inculcate the notion. How would such a long lifespan affect our sense of self? Would institutions and mores such as lifelong marriage and monogamy remain the norm? When would we retire? How would our relationships with the many subsequent generations of our family be shaped? How would population growth be managed? How would such long lives be funded?

Such questions are, for sure, of no concern to those currently in cryostasis. These people tend to be into sci-fi, and into science too, suggests Kowalski, who has signed up himself, his wife and children for cryonic services when the time comes. I think for a lot of them its not necessarily about the fear of death. Its more a fascination with the future. Theyre optimistic about what it will bring. Theyre more Star Trek than Terminator.

Visit link:
This Company Freezes Your Body So That You Could One Day Be Resurrected – Billionaire BLLNR | Singapore (registration)

Recommendation and review posted by sam

Controversial Genetic Testing Company in Receivership – Pain News Network

In June, FBI agents raided the companys headquarters in Irvine, California. Former and current employees who were interviewed by STAT said the agents were focused on possible kickbacks to doctors who encouraged patients to take Prooves DNA tests. Physicians reportedly could make $144,000 a year in kickbacks that were called research fees.

In July, PNN reported that Proove was linked to a Medicare fraud case, in which three Indiana healthcare providers allegedly caused Proove Bioscience to falsely and fraudulently bill various health care programs for genetic tests… that were not medically necessary and never interpreted.”

Proove was not named as a defendant in the Indiana case. In an email to PNN, Meshkin said Proove had cooperated with investigators.

Proove has cooperated with both the FBI and US Attorneys office on this case,” said Meshkin. “With regards to tests being ‘medically necessary’, Proove received written and signed determinations of medical necessity supporting the tests ordered and billed to insurance carriers just like every other laboratory which requires such a determination on a test requisition form. Thus Proove operated appropriately and consistent with usual and customary practices.”

Meshkin also defended Proove research, published in the Journal of Addiction Research & Therapy, which claimed to show the effectiveness of its genetic tests.The publisher of the journal, OMICS International, has been accused by the Federal Trade Commission (FTC) of deceiving researchers and readers about the true nature of its publications and peer review process.

“Proove can only speak to its experience with this particular journal, Meshkin said in an email to PNN. “Specifically for papers submitted to this journal, our R&D team and academic collaborators engaged in documented, extensive peer-review, received suggested edits and provided responses to the suggested edits to the manuscripts submitted for review and publication. Thus, Proove would certainly consider the publications accepted from Proove-affiliated authors in that journal to be ‘peer-reviewed’.”

According to the FTC complaint filed last August, OMICS has created hundreds of “open access” online medical journals that publish articles with little or no peer review. Researchers are also charged significant fees to get their articles published by OMICS, a “pay to play” policy that some consider unethical because it diminishes the quality of academic journals and the peer review process.

Proove has aggressively promoted its genetic tests with healthcare providers around the country. A pain clinic in Montana, for example, had a Proove patient engagement representative employed on site at the Benefis Pain Management Center in Great Falls.

We had a meeting one day and here are these people from Proove Biosciences. They told us they were doing a research project, said Rodney Lutes, a physician assistant who was later fired by Benefis. They wanted to come to Benefis, into the pain department, and test our patients. We were told this would be at no cost to the patient. My understanding was that they werent going to charge anybody, but I found out afterwards they were charging insurance companies.

They said providers who participated in this would get some form of payment for participating in the program and for filling out all the paperwork.

Lutes supervising physician at the clinic was Katrina Lewis, MD, a pain management specialist at Benefis who is listed as a member of Prooves Medical Advisory Board. Lewis apparently plays a significant role at the clinic, even though she only works there part time. Benefis has denied that Lewis or any of its employees received kickbacks from Proove for referring business to them.

STAT reported that Prooves restructuring was apparently ordered by Mike Leavitt, a Proove board member, who also served as Utah governor and secretary of the Department of Health and Human Services. Leavitts investment firm, Leavitt Equity Partners, provided about $7 million in funding to Proove, according to Meshkin.

A former Proove manager told STAT that she initially felt good about going to work for the company, but soon had misgivings about Proove’s research and billing practices.

It sucked the life out of me, on an integrity level, said Rhonda Frantz-Smith. It got more and more corrupt.

Read the original post:
Controversial Genetic Testing Company in Receivership – Pain News Network

Recommendation and review posted by simmons

Open Longevity Project: a Scientific Approach to Conquer Aging – Blockchain News

A new project in the field of biotechnology, telemedicine, clinical research and medical services is completing preparations for pre-ICO. Open Longevity is organizing research of anti-aging therapies in humans by providing online advisory services. Their ultimate goal is to find and introduce effective methods of radical life extension into clinical practice. Therefore, the tokens are called YEAR.

The project claims they will combine the capabilities of modern IT-systems, the expertise of leading scientific analysts and the energy of the patients themselves. Another driving force they emphasize is openness and rejection of commercial benefits in those matters where this can affect the objectivity of scientific research.

One of the common concerns, when antiaging drugs are being mentioned, is that, once proven effective, anti-aging medicine will become available only to the elite. The fact that the trials results will belong to the patients community, might be a possible solution to this potential problem.

Mikhail Batin, the CEO of Open Longevity, states he is sure that effective ways to delay the onset of aging will be foundit is only a matter of time. He and his colleagues just want to accelerate the research.

The project consists of two parts: clinical trials and online service. Part of the funds raised through ICO will be spent on the first three studies: Longevity Diet-1 (a variant of a fasting mimicking diet); Alzheimers disease therapy (vitamin B12) and atherosclerosis therapy (sartans + statins). One can even find documents for the first trial in progress, though just in Russian yet. As the trial is planned to be submitted to NIHs https://clinicaltrials.gov, the documents will be translated into English at some point.

All the subsequent studies will later be also funded: life extension projects are expected to be submitted for voting on a general basis, voting will be conducted among all the YEAR token holders.

All clinical trials will be carried out in strict accordance with existing norms. Thus CROs (contract research organizations), laboratories, and clinical institutions that traditionally carry out similar research, will be involved. But OL team is already talking about making all paperwork more automated.

Another part of the funds will be spent on creating an online platform. By uploading biomedical data, users will be able to monitor their health and aging status in dynamics; receive recommendations from specialists and expert system based on AI; and also become volunteers in trials.

The service will be accessible to everyone. But payment with YEAR tokens is promised to be more favorable than paying with fiat currencies due to 50% discount. This, among other points mentioned in projects WP, has to maintain a constant token flow within the system and ensure the stability of its exchange rate.

The first three days of pre-ICO is going to be in the format of Private Placement. The registration has started already, but the date of preICO launch itself will be announced in advance in projects channels in Telegram.

Related

advertisement

Read the original post:
Open Longevity Project: a Scientific Approach to Conquer Aging – Blockchain News

Recommendation and review posted by Bethany Smith

Texas relief funds benefit farmers and ranchers – Kotatv

RAPID CITY, S.D. (KOTA TV) – Hurricane Harvey is still wreaking havoc in Texas, and South Dakota farmers and ranchers are no stranger to the affects of Mother Nature.

“What the country did for South Dakota ranchers and particularly those ranchers in our neck of the woods was awesome, said Kadee Handee, marketing manager of the Black Hills Stock Show and Central States Fair. We want to make sure that your donation will go to an organization that will truly use it.”

Hurricane Harvey has displaced many families from their home, but also cattle from their pastures.

According to the U.S. Department of Agriculture, about 1.2 million beef cows are registered in the 54 counties that have been declared as disaster areas.

Hundreds of pets have been rescued from the rising waters as well. If you are interested in donating to that cause, seek out local shelters in Houston and San Antonio.

But there are other ways to donate as well. Tangible donations like hay, resources and even animals can be made to the Agri-Life Extension.

“It is an arm of the Extension Agency in Texas that will be able to facilitate those demands and facilitate those resources to those ranchers that are affected, said Handee

The Texas FFA Association and the Texas A&M Veterinary Emergency Team are some more reputable organizations that are accepting donations for relief funds.

Donations can also be mailed to: Cattleraisers Relief1600 Gindy St. Ft. Worth, TX 76107

Go here to see the original:
Texas relief funds benefit farmers and ranchers – Kotatv

Recommendation and review posted by simmons


Archives